Cell Therapeutics Announces Receipt of NASDAQ Panel Decision to Transfer to NASDAQ Capital Market
T: 206.272.4343 C: 206.854.1200 E: media@ctiseattle.com http://www.CellTherapeutics.com/press_room Investors Contact: Ed Bell T: 206.272.4345 Lindsey Jesch Logan T : 206.272.4347 F : 206.272.4434 E: a hrefmailto:invest@ctise
Date:1/6/2009